DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for long QT syndrome 16 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLong QT syndrome 16 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for long qt syndrome 16 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
calmodulin 3 (CALM3) — CALM3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8KA0 · 2.35 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
The abstracts provided do not contain any data specific to long QT syndrome 16, nor do they report on any drug repurposing trials for that subtype. They are general reviews and expert commentaries on congenital long QT syndrome as a whole. One 2006 review states that genetic testing will determine the defect in as many as 75% of subjects in a family with suspected disease, leaving the gene defect unknown in the remaining 25%. The mainstay of therapy across these sources is consistently described as beta-blockers, with implantable cardioverter-defibrillators reserved for patients at high risk of malignant arrhythmias. No response rates, survival statistics, or sample sizes from interventional studies are given in any of the abstracts.
A 2021 commentary from 24 experts found consensus on the importance of diagnostic evaluation and beta-blocker use, but documented significant diversity of opinion regarding other therapeutic measures in intermediate-risk individuals. The authors identified significant gaps in knowledge, particularly in applying guidelines to individual patients. A separate 2021 article is a descriptive review of diagnostic criteria and risk factors, offering no new clinical trial evidence. The 2003 abstract estimates the prevalence of the disorder at between 1:10,000 and 1:5,000, but again provides no therapeutic outcome data.
There is no evidence in these abstracts for any specific drug being repurposed for long QT syndrome 16, and no mention of any experimental treatment beyond beta-blockers. The literature presented is limited to diagnostic and management frameworks that predate or do not address the specific genetic subtype. What is missing is any prospective trial data for this particular mutation, a defined patient cohort stratified by genotype, and funding for studies that could test whether any existing compound alters outcomes in long QT syndrome 16 specifically.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2006 · 38 citations
Advances in congenital long QT syndrome
AbstractPURPOSE OF REVIEW: Dramatic advances have been made in understanding of both the genetics and the phenotypic expression of congenital long QT syndrome. This paper reviews recent clinically relevant literature. RECENT FINDINGS: Long QT syndrome is one of the leading causes of sudden cardiac death. This syndrome, once diagnosed by a clinical profile, has been more clearly defined by specific gene defects causing ion channel abnormalities in the beating heart. Genetic testing for long QT syndrome, once available only through research laboratories, is now commercially available. Diagnosis, risk assessment, and management are increasingly being guided by gene-specific diagnoses. In a family with suspected disease, the genetic test will determine the defect in as many as 75% of subjects. Once the diagnosis is made, the mainstay of therapy continues to be beta-blockers. Implantable cardioverter-defibrillators are indicated in patients at high risk for malignant arrhythmias. SUMMARY: Long QT syndrome is one of the first cardiovascular diseases to see the dramatic changes that bench research can bring to the clinical arena. Future research is needed to determine the gene defect in the remaining 25% of patients with suspected long QT syndrome and in risk stratification.
Circulation Arrhythmia and Electrophysiology · 2021 · 19 citations · open access
Management of Congenital Long-QT Syndrome: Commentary From the Experts
AbstractWhile published guidelines are useful in the care of patients with long-QT syndrome, it can be difficult to decide how to apply the guidelines to individual patients, particularly those with intermediate risk. We explored the diversity of opinion among 24 clinicians with expertise in long-QT syndrome. Experts from various regions and institutions were presented with 4 challenging clinical scenarios and asked to provide commentary emphasizing why they would make their treatment recommendations. All 24 authors were asked to vote on case-specific questions so as to demonstrate the degree of consensus or divergence of opinion. Of 24 authors, 23 voted and 1 abstained. Details of voting results with commentary are presented. There was consensus on several key points, particularly on the importance of the diagnostic evaluation and of β-blocker use. There was diversity of opinion about the appropriate use of other therapeutic measures in intermediate-risk individuals. Significant gaps in knowledge were identified.
Public health of the Far East Peer-reviewed scientific and practical journal · 2021 · 3 citations
Long QT interval syndrome
AbstractThe article provides an analysis of modern literature on the problem of diagnosing the long QT syndrome. The diagnostic criteria of this syndrome, features of rare congenital and acquired forms of the disease are described in the article. Risk factors for the development and diagnostic criteria of this disease are presented.
AbstractThe Long QT syndrome (LQTS) is an inherited arrhythmogenic disease occurring in the structurally normal heart that may cause sudden death and that usually manifests in children and teen-agers (1). The prevalence of this disorder is still undefined, however it is estimated to be between 1:10000–1:5000.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
